KRAS and non-small cell lung carcinoma: Next, to further clarify whether the RAS/RAF pathway was involved in ALDH2-mediated PTX resistance, we overexpressed KRAS and RAF1, and determined the efficacy of PTX in ALDH2 knockdown NSCLC/PTX cells (Fig. S6C).